

Oncology Today with Dr Neil Love: PARP Inhibitors in Breast Cancer Edition  
(Audio Interview)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results from the placebo-controlled Phase III BROCADE 3 trial demonstrated a progression-free survival benefit with which of the following PARP inhibitors in combination with carboplatin/paclitaxel for patients with HER2-negative metastatic breast cancer with germline BRCA mutations?
  - a. Olaparib
  - b. Talazoparib
  - c. Veliparib
  - d. Niraparib
2. What is the incidence of germline BRCA1/2 mutations among patients with triple-negative breast cancer?
  - a. 1% to 3%
  - b. 5% to 10%
  - c. 10% to 15%
3. The Phase III OlympiA trial is evaluating olaparib for patients with high-risk HER2-negative breast cancer and germline BRCA1/2 mutations in which setting?
  - a. Neoadjuvant
  - b. Adjuvant
  - b. Metastatic
4. Which of the following PARP inhibitors is most frequently associated with thrombocytopenia?
  - a. Olaparib
  - b. Niraparib
  - c. Talazoparib